3M Company (MMM)
NYSE: MMM · Real-Time Price · USD
170.76
+11.65 (7.32%)
At close: Jul 21, 2026, 4:00 PM EDT
170.75
-0.01 (-0.01%)
After-hours: Jul 21, 2026, 7:59 PM EDT

3M Company Earnings Call Transcripts

Fiscal Year 2026

  • Q2 delivered 5.4% organic growth, 24.9% operating margin, and 11% EPS growth, prompting raised full-year guidance for sales, EPS, and free cash flow. Strong performance was driven by commercial excellence, innovation, and robust segment results, with continued momentum expected.

  • Momentum is building across all segments, driven by commercial excellence, innovation, and operational improvements. Strong order growth, successful price increases, and targeted portfolio actions are supporting above-macro growth and margin expansion, with continued acceleration expected in the second half of the year.

  • AGM 2026

    Shareholders elected all director nominees, ratified the auditor, and approved executive compensation. Organic growth and new product launches accelerated, with strong returns to shareholders and a focus on innovation and operational excellence. Geopolitical risks are being closely monitored.

  • Q1 delivered strong EPS and margin growth, with robust order momentum and backlog supporting an optimistic outlook. Automation, portfolio reshaping, and new product launches are driving productivity and positioning for higher growth, despite macro and oil price uncertainties.

  • Management is driving growth through operational and innovation excellence, with strong industrial performance and a robust pipeline of new products. Margin expansion and portfolio optimization remain key, while legal liabilities are being actively managed and insurance recoveries continue.

Fiscal Year 2025

  • Q4 and full-year results showed strong organic growth, margin expansion, and robust cash flow, driven by commercial excellence and innovation. 2026 guidance calls for continued sales and margin growth, with ongoing transformation and capital returns to shareholders.

  • The event highlighted ongoing transformation through operational discipline, innovation, and commercial excellence, with strong progress on new product launches, productivity, and margin expansion. Despite mixed end-market trends, the outlook remains positive, with a focus on growth, cost management, and portfolio optimization.

  • Q3 delivered 3.2% organic sales growth, 170 bps margin expansion, and 10% EPS growth, driven by commercial excellence and new product launches. Full-year EPS guidance was raised, with strong cash flow and continued portfolio optimization.

  • Management is executing on a back-to-basics strategy focused on innovation, operational excellence, and portfolio optimization, with strong progress in new product launches, margin expansion, and commercial execution. Growth is expected to accelerate, supported by improved asset utilization, divestitures of non-core businesses, and a disciplined approach to litigation and PFAS exit.

  • Q2 delivered strong results with adjusted EPS up 12% year-over-year, margin expansion, and robust free cash flow. All business groups grew, driven by productivity, new product launches, and commercial excellence, while guidance was raised despite ongoing PFAS litigation and tariff headwinds.

  • Settled major PFAS claims with New Jersey, reducing long-term risk and freeing capital for strategic priorities. Operational excellence, innovation, and commercial initiatives are driving margin improvement and growth, despite a softening macro environment. R&D and culture transformation remain central to future performance.

  • AGM 2025

    Shareholders elected all board nominees, ratified auditors, and approved executive compensation with strong support. Strategic priorities include innovation-driven growth and operational excellence, while a major legal settlement and tariff impacts were discussed.

  • Q1 delivered 10% EPS growth and margin expansion, with strong free cash flow and broad-based organic sales gains. Guidance remains cautious due to macro softness and tariff risks, but mitigation plans and commercial initiatives are underway to offset headwinds.

  • Management outlined a renewed focus on operational execution, innovation, and customer-centric culture, maintaining 2025 EPS guidance and targeting high single-digit growth in subsequent years. Strong order flow is offset by delayed revenue, with cost controls supporting margins. PFAS litigation remains a risk, but leadership is optimistic about long-term value and shareholder returns.

  • Investor Day 2025

    A new integrated operating model and performance culture are driving 1,000 new product launches, $1B in productivity, and a shift to high-growth markets. Financial targets include 25% operating margin by 2027, high single-digit EPS growth, and $10B in shareholder returns, underpinned by rigorous execution and capital discipline.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Fiscal Year 2017

Fiscal Year 2016

Fiscal Year 2015